SuperworthLivaNova LIVN
- Market cap
- $4.5B
- PE
- 23.9×
- 9y median 72.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.0×
- EV/EBIT
- 22.6×
- Revenue, 12 months
- $1.5B
- +12% on a year ago
- Net margin
- 12.8%
- Free cash flow yield
- 3.3%
LivaNova trades at 23.9× trailing earnings, cheaper than 90% of the last ten years. Revenue was $1.5B over the last twelve months, up 12% on a year earlier with a 13% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $286.1M+13% | $310.1M+13% | $294.9M+12% | $318.6M+8% | $318.1M+11% | $321.8M+4% | $316.9M+7% | $352.5M+11% | $357.8M+13% | $360.9M+12% | $362.3M+14% | $390.6M+11% | |
| Cost of revenue | $84.3M+3% | $120M+31% | $87.5M−2% | $103.7M+17% | $97.1M+15% | $102.5M−15% | $100.6M+15% | $113.5M+10% | $112.9M+16% | $121.1M+18% | $118.5M+18% | $116.9M+3% |
| Gross profit | $201.8M+18% | $190.2M+4% | $207.4M+19% | $214.9M+5% | $221M+10% | $219.4M+15% | $216.3M+4% | $239M+11% | $244.9M+11% | $239.8M+9% | $243.7M+13% | $273.7M+15% |
| R&D | $46.5M+30% | $46.2M+3% | $45.7M−9% | $44.7M−13% | $48.8M+5% | $43.3M−6% | $37.9M−17% | $47.2M+6% | $48.6M−1% | $52.1M+20% | $58.7M+55% | $53.7M+14% |
| SG&A | $134.8M+18% | $133.3M+12% | $129.9M+5% | $125.1M−1% | $127.4M−6% | $135.6M+2% | $129.1M−1% | $137.8M+10% | $138.5M+9% | $143.4M+6% | $143.6M+11% | $158.1M+15% |
| $4.5M | −$88M | $16.2M | $40.2M+131% | $35.6M+699% | $37M | $48.6M+199% | $54.2M+35% | $54M+52% | $42.6M+15% | $41.5M−15% | $49.5M−9% | |
| Interest expense | $15M+18% | $15.6M+17% | $15.9M+18% | $15.5M+5% | $15.9M+6% | $15.8M+1% | $15.3M−4% | $14.9M−4% | $10.9M−32% | $10.9M−31% | $8.3M−46% | $7.2M−52% |
| Pre-tax income | −$2M−98% | −$94.3M | −$34.2M | $21.6M+309% | $44.4M | $56.5M | −$315.6M+823% | $33.3M+54% | $33.9M−24% | $27.6M−51% | $27.5M | $18.5M−45% |
| $5.3M+310% | −$110.7M | $7.7M+226% | $5.2M+28% | $11.5M+117% | $589K | $11.7M+51% | $6.2M+18% | $7.1M−38% | −$3.3M | $4.3M−63% | −$90.2M | |
| Net income | −$7.3M−93% | $16.3M+884% | −$41.9M | $16.3M+1314% | $33M | $55.9M+242% | −$327.3M+680% | $27.2M+66% | $26.8M−19% | $30.9M−45% | $22.3M | $108.6M+300% |
| −$0.14−93% | $0.30+900% | −$0.78 | $0.30+1400% | $0.60 | $1.02+240% | −$6.01+671% | $0.50+67% | $0.49−18% | $0.57−44% | $0.40 | $1.93+286% | |
| 54M+1% | 54.5M+2% | 54M+0% | 54.6M+1% | 54.6M+1% | 54.7M+0% | 54.4M+1% | 54.7M+0% | 55.2M+1% | 54.6M−0% | 55.9M+3% | 56.3M+3% |
Cost of revenue: Q2 FY14: 6 months less the 3 months printed beside them.
Gross profit: 8 periods, Q1 FY18 to Q4 FY19: not printed by the filing, worked out from its own lines.
R&D: Q2 FY14: 6 months less the 3 months printed beside them.
SG&A: Q2 FY14: 6 months less the 3 months printed beside them.
Operating income: Q2 FY14: 6 months less the 3 months printed beside them.
Pre-tax income: Q2 FY14: 6 months less the 3 months printed beside them.
Income tax: Q2 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 13 periods, Q2 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q2 FY14: share-days: the 6-month average less the second quarter's. Q4 FY15: a loss quarter: its basic count, share-days: the 9-month average less the 6-month, weighted by days. 6 periods, Q4 FY16 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY22 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Devices nearest LivaNova's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LIVNLivaNova | $4.5B | 23.9× | 72.5× | n/m | 3.0× | +12% | 12.8% |
| ITGRInteger | $4.3B | 34.6× | 33.5× | n/m | 2.3× | +3% | 7.0% |
| TMDXTransMedics | $2.5B | 18.4× | 56.8× | n/m | 3.7× | +26% | 22.7% |
| CNMDCONMED | $1.5B | 26.6× | 53.0× | n/m | 1.1× | +3% | 4.1% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| Peer median | $11.6B | 25.3× | 43.3× | 20.8× | 2.3× | +8% | 9.4% |
More on LivaNova
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 13Medical device stocks with the lowest PE ratio
- #8of 17Medical device stocks with the highest profit margins
- #9of 17Medical device stocks with the fastest revenue growth
- #7of 13Medical device stocks with the lowest EV/EBIT
- #9of 13Medical device stocks with the highest free cash flow yield
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .